“compound 9” is an investigational prodrug of pibrentasvir (ABT-530), a key component of AbbVie’s marketed HCV combination Mavyret. Pibrentasvir (PIB) is the largest approved oral small molecule since 1983 (MW = 1113, not including the peptide semaglutide at MW = 4113), and came with some solubility issues (aq. sol. pH 7 = <0.0001 mg/mL). The [...]
< 1 minute read
Sep. 18, 2021
"compound 9": Pibrentasvir Prodrug Improves Solubility
"compound 9"
trimethyl-lock prodrug of HCV NS5A inh. improved bioavailability in preclinical species from derivatization of pibrentasvir J. Med. Chem., Sep. 3, 2020 AbbVie, North Chicago, IL
Loading...
